Q-omics provides the consensus-scored PLXDC2 profile across patient tissues and cancer cell-line models. PLXDC2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLXDC2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PLXDC2 protein abundance shows 23,816 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where PLXDC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLXDC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLXDC2 survival associations across molecular data types. PLXDC2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLXDC2 RNA expression–survival associations across cancer types. High PLXDC2 expression shows unfavorable associations in STAD, UVM and BLCA, but favorable associations in KIRC, SKCM and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PLXDC2 RNA expression.
This table summarizes PLXDC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLXDC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLXDC2 shows lower tumor expression in UCEC, KICH, LUAD and BLCA and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher PLXDC2 RNA expression in tumor versus normal tissue (log2 FC = +0.773, t-test p < 0.001).
This table shows molecular features associated with PLXDC2 in patient tissues and cancer cell lines. In patient samples, PLXDC2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLXDC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
